Xenon Pharmaceuticals  logo
Xenon Pharmaceuticals XENE
$ 37.93 -2.19%
report update icon

Quarterly report 2026-Q3
added 11-09-2026

Xenon Pharmaceuticals Revenue | XENE

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Xenon Pharmaceuticals

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
7.5 M - - 9.43 M 18.4 M 32.2 M 6.83 M - 311 K 1.8 M 15.6 M 28.4 M 27.4 M 14.3 M 6.92 M

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
32.2 M 311 K 14.1 M

Quarterly Revenue Xenon Pharmaceuticals

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- - - - - - 7.5 M - - - - - - - - - 132 K 536 K 8.77 M 3.74 M 8.12 M 2.22 M 4.36 M 5.15 M 6.55 M 13.4 M 7.08 M 3.33 M 3.5 M - - - - - - 16 K 264 K 15 K 16 K 376 K 413 K 413 K 601 K 3.23 M 4.29 M 4.05 M 4.01 M 4.88 M 13.2 M 5.3 M 5 M 5.58 M 10.8 M 5.6 M 5.38 M - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
13.4 M 15 K 4.35 M

References

  1. Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer Revenue Price % 24h Market Cap Country
Brickell Biotech Brickell Biotech
BBI
8.01 M - -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
455 K - - $ 8.42 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
19.9 M - - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
1.66 M - - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
36.1 M - - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
1.53 M - - $ 2.36 B usaUSA
Acasti Pharma Acasti Pharma
ACST
100 M - 4.01 % $ 150 M canadaCanada
Galapagos NV Galapagos NV
GLPG
1.11 B - - $ 1.83 B belgiumBelgium
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
1.1 M - -4.36 % $ 27 M usaUSA
Idera Pharmaceuticals Idera Pharmaceuticals
IDRA
4.86 M - -23.04 % $ 26.6 M usaUSA
Verona Pharma plc Verona Pharma plc
VRNA
42.3 M - - $ 69.7 B britainBritain
Avenue Therapeutics Avenue Therapeutics
ATXI
1.4 M - -52.27 % $ 4.45 M usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
2.04 M $ 4.63 21.05 % $ 20 M israelIsrael
Achieve Life Sciences Achieve Life Sciences
ACHV
5.06 M $ 6.78 0.89 % $ 296 M usaUSA
Leap Therapeutics Leap Therapeutics
LPTX
1.5 M - 368.57 % $ 41.9 M usaUSA
Guardion Health Sciences Guardion Health Sciences
GHSI
12.2 M - -0.31 % $ 3.64 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
47.8 M - - $ 109 M usaUSA
ImmunoGen ImmunoGen
IMGN
109 M - - $ 7.92 B usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
310 K - -8.77 % $ 12.4 M israelIsrael
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
48.2 B $ 59.5 -3.02 % $ 121 B usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
1.28 M - - $ 1.41 B usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
1.18 M $ 1.1 -1.79 % $ 2.71 B israelIsrael
Iterum Therapeutics Iterum Therapeutics
ITRM
37 K - - $ 591 K irlandaIrlanda
Navidea Biopharmaceuticals Navidea Biopharmaceuticals
NAVB
65.7 K - -2.99 % $ 2.47 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
21.1 M - - $ 23.9 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
167 M - -4.8 % $ 255 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
40.6 M - -0.23 % $ 916 M usaUSA
bluebird bio bluebird bio
BLUE
83.8 M - - $ 546 M usaUSA
Landos Biopharma Landos Biopharma
LABP
18 M - 0.58 % $ 144 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
43.1 M - - $ 35.4 M usaUSA
Sigilon Therapeutics Sigilon Therapeutics
SGTX
12.9 M - - $ 728 M usaUSA
NGM Biopharmaceuticals NGM Biopharmaceuticals
NGM
4.42 M - - $ 127 M usaUSA
Regulus Therapeutics Regulus Therapeutics
RGLS
10 M - - $ 155 M usaUSA
Aravive Aravive
ARAV
9.14 M - -13.39 % $ 1.45 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
1.26 M - 2.71 % $ 14 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
277 M - - $ 2.02 B usaUSA
Turning Point Therapeutics Turning Point Therapeutics
TPTX
30.8 M - -0.13 % $ 3.73 B usaUSA
Orgenesis Orgenesis
ORGS
1.04 M - -33.86 % $ 61.2 M usaUSA